Treatment sequencing studies revealed that initiating with <sup>125</sup>I brachytherapy followed by combination therapy with PD-L1 antibody and Abraxane resulted in the most favorable outcome, confirming this "<sup>125</sup>I-first" approach as an effective immune priming strategy.<h4>Discussion</h4>This study demonstrates that <sup>125</sup>I brachytherapy overcomes the limitations of conventional radiotherapy by inducing sustained immunogenic cell death, remodeling the tumor immune microenvironment, and activating systemic antitumor immunity. This evidence concerns the gene CD274 and neoplasm.